Effectiveness of Parent-Led Interventions in Reducing Infant Hypersensitivity to Pain

NCT ID: NCT01503060

Last Updated: 2015-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

352 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to find out the effects of routinely using different types of pain-relieving strategies during routine immunization injections performed in infants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

* Visit 1-4 (2,4,6,12 month vaccinations): Patients will receive standard care
* Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions.

Group Type PLACEBO_COMPARATOR

Educational Video - Sham

Intervention Type BEHAVIORAL

The sham video will provide general information about immunization immunization pain management.

Sucrose Placebo (water)

Intervention Type DRUG

Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination

Lidocaine Placebo

Intervention Type DRUG

Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination

Group 2

* Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain
* Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions.

Group Type ACTIVE_COMPARATOR

Educational video - Active

Intervention Type BEHAVIORAL

The active video will instruct parents in techniques related to optimal infant soothing.

Sucrose Placebo (water)

Intervention Type DRUG

Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination

Lidocaine Placebo

Intervention Type DRUG

Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination

Group 3

* Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain and their infant will be given sugar
* Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions.

Group Type ACTIVE_COMPARATOR

Educational video - Active

Intervention Type BEHAVIORAL

The active video will instruct parents in techniques related to optimal infant soothing.

Sucrose

Intervention Type DRUG

Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination

Lidocaine Placebo

Intervention Type DRUG

Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination

Group 4

* Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain and their infant will be given sugar water and a topical anesthetic
* Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions.

Group Type ACTIVE_COMPARATOR

Educational video - Active

Intervention Type BEHAVIORAL

The active video will instruct parents in techniques related to optimal infant soothing.

Sucrose

Intervention Type DRUG

Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination

Lidocaine

Intervention Type DRUG

Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Educational video - Active

The active video will instruct parents in techniques related to optimal infant soothing.

Intervention Type BEHAVIORAL

Educational Video - Sham

The sham video will provide general information about immunization immunization pain management.

Intervention Type BEHAVIORAL

Sucrose Placebo (water)

Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination

Intervention Type DRUG

Sucrose

Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination

Intervention Type DRUG

Lidocaine Placebo

Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination

Intervention Type DRUG

Lidocaine

Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1\. Healthy infants undergoing vaccination.

Exclusion Criteria

1. preterm birth (\<37 weeks gestation)
2. prior hospitalization/surgery (other than postnatal care),
3. documented/ suspected sensitivity/allergy to amide anaesthetics/vaccines,
4. mother plans to breastfeed or to use topical anesthetics or sugar water during injection.
Minimum Eligible Age

2 Months

Maximum Eligible Age

15 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Hospital for Sick Children

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Anna Taddio

Adjunct Scientist/Pharmacist

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anna Taddio, PhD

Role: PRINCIPAL_INVESTIGATOR

The Hospital for Sick Children

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Outpatient Clinic

Toronto, Ontario, Canada

Site Status RECRUITING

The Hospital for Sick Children

Toronto, Ontario, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Anna Taddio, PhD

Role: CONTACT

416-813-6235

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Moshe Ipp, MD

Role: primary

(416) 924-7171

Anna Taddio, PhD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Taddio A, Riddell RP, Ipp M, Moss S, Baker S, Tolkin J, Dave M, Feerasta S, Govan P, Fletcher E, Wong H, McNair C, Mithal P, Stephens D. A Longitudinal Randomized Trial of the Effect of Consistent Pain Management for Infant Vaccinations on Future Vaccination Distress. J Pain. 2017 Sep;18(9):1060-1066. doi: 10.1016/j.jpain.2017.04.002. Epub 2017 Apr 26.

Reference Type DERIVED
PMID: 28455250 (View on PubMed)

Taddio A, Riddell RP, Ipp M, Moss S, Baker S, Tolkin J, Malini D, Feerasta S, Govan P, Fletcher E, Wong H, McNair C, Mithal P, Stephens D. Relative effectiveness of additive pain interventions during vaccination in infants. CMAJ. 2017 Feb 13;189(6):E227-E234. doi: 10.1503/cmaj.160542. Epub 2016 Dec 12.

Reference Type DERIVED
PMID: 27956393 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1000025726

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.